Phaseline

Companies › Wuhan YZY Biopharma

Wuhan YZY Biopharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
M701
anti-EpCAM and anti-CD3 human-mouse chimeric bispecific antibody
EPCAM, CD3EPhase 3Malignant Ascites; Malignant Pleural EffusionsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06432296M701Phase 3Malignant AscitesOncologyDec 2026
NCT05543330M701Phase 1Malignant Pleural EffusionsOncologyDec 2026

Targets

EPCAM (1) CD3E (1)

Companies with the same targets

Johnson & Johnson (Janssen) BioAtla Regeneron Pharmaceuticals Amgen Roche AstraZeneca AcadeMab Biomedical Mirador Therapeutics Tiziana Life Sciences Sanofi

Companies built like this

LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company Quercis Pharma ABX advanced biochemical compounds

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.